Document:

EX-10.2

 Exhibit 10.2 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 

Co-operation Agreement 
  

			
	Between:	  	ACADIA Pharmaceuticals GmbH
		  	Pilatusstrasse 41
		  	6003 Lucerne
		  	Switzerland
		  	(hereinafter called ACADIA)
		
	And	  	BASF Pharma (Evionnaz) SA
		  	route du Simplon 1
		  	1902 Evionnaz
		  	Switzerland
		  	(hereinafter called BPE)
		
	Recitals:	  	

 Whereas, BPE sells and markets pharmaceutical products manufactured by it and its Affiliates (as defined
below), e.g. BASF Pharma (Saint-Vulbas) SAS (“BPSV”), BASF PharmaChemikalien GmbH & Co. KG (“BPCG”) as well as BASF SE in Germany (“BASF”). 

Whereas, BPE and/or one of its Affiliates have the ability and desire to manufacture and BPE has the desire to supply the PRODUCT (as defined
in clause 1.1 herein). BPSV, BPCG, and BASF are referred to in this Agreement, collectively, as “Affiliates” of BPE and, individually, as an “Affiliate” of BPE. 

Whereas, ACADIA is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the
treatment of central nervous system disorders and is incorporated in Switzerland. 
 BPE and ACADIA are referred to herein, collectively, as
the “Parties” and, individually, as a “Party”. 
  

	1.	Preamble 

  

	1.1.	The Parties wish to co-operate in the industrial scale manufacture of the products described in more detail in the PRODUCT schedules (essentially in the form as stipulated in Annex A hereto) hereto (hereinafter called
PRODUCTS), and to establish the framework under which such co-operation is to be undertaken. 

  

	2.	Co-operation scope: 

  

	2.1.	 The Parties agree to co-operate on the terms of this Agreement to manufacture PRODUCTS at BPE and/or its Affiliates, as indicated in more
detail in the relevant PRODUCT schedule hereto, and to support the supply of the PRODUCT by BPE to ACADIA. ACADIA understands that the PRODUCTS are manufactured for ACADIA (including its affiliates and its

	 	
and their respective licensees and collaborators) only and that once the PRODUCTS have been manufactured in accordance with the terms of this Agreement and the relevant PRODUCT schedule,
including but not limited to the forecasting and order procedures (and meet the warranties in Section 3.2), ACADIA shall purchase them on a first in first out basis as established in the relevant PRODUCT schedule; provided, however, that
ACADIA shall not have any obligation to purchase PRODUCTS in quantities that exceed quantities reflected in a binding PRODUCT schedule. 

  

	2.2.	The individual manufacturing program to be undertaken by BPE to manufacture a specific PRODUCT is set out in the respective PRODUCT schedule (hereinafter called the Manufacturing Program).

  

	 	2.2.1.	BPE hereby agrees to use commercially reasonable efforts and all due skills and care to conduct the Manufacturing Program and to provide or cause its Affiliates indicated in the PRODUCT schedule to provide
adequate and appropriate resources required to complete the Manufacturing Program. 

  

	 	2.2.2.	ACADIA hereby agrees to provide BPE and its Affiliates appropriate resources to the extent reasonably required by BPE, or its Affiliates, as provided in the relevant PRODUCT schedule. Upon
reasonable advance notice during normal business hours, ACADIA will make available to BPE and its Affiliates ACADIA personnel to respond to queries and requests from BPE and its Affiliates. 

 

	2.3	The terms for lead times, forecasts and orders shall be individually agreed upon for each PRODUCT in the relevant PRODUCT schedule. 

 

	3.	Obligations of BPE 

  

	3.1.	BPE shall manufacture or have manufactured (by its Affiliates) and supply to ACADIA the PRODUCTS in accordance with current Good Manufacturing Practices as stipulated in the ICH Harmonized
Tripartite Guideline Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7 (“cGMP”), and the specifications mutually agreed upon in the respective PRODUCT schedule. Notwithstanding anything to the contrary in this
Agreement, the PRODUCT schedule or the corresponding quality agreement entered into by the Parties (as may be amended by the Parties from time to time in accordance with its terms, the “Quality Agreement”), in no event may BPE initiate or
perform any manufacturing or other activities under this Agreement through any Affiliates of BPE, or any subcontractor, without the prior written approval by ACADIA. BPE acknowledges that, prior to initiating any activities at an Affiliate of BPE or
any subcontractor, such sites must be qualified by ACADIA. 

  

	3.2.	 BPE represents and warrants that PRODUCTS supplied under this Agreement shall: (i) be manufactured in accordance with applicable

  
 2 

	 	
regulatory approvals for such PRODUCTS, cGMP and all other applicable laws and regulations, (ii) conform to the specifications agreed upon in the respective PRODUCT schedule in
effect at the time of delivery, (iii) not be adulterated or misbranded within the meaning of the U.S. Federal Food, Drug & Cosmetic Act, as amended from time to time, and/or any analogous regulations in any other applicable
jurisdiction, (iv) not contain any defect in material or workmanship or any cross-contamination, and (v) at the time of delivery, be free and clear of any lien or encumbrance. 

 

	3.3.	BPE MAKES NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, BY FACT OR LAW, OTHER THAN (I) AS SET FORTH IN SECTION 3.2, AND (II) IMPLIED WARRANTIES OF TITLE, FREEDOM FROM ENCUMBRANCE, AND RIGHT TO
TRANSFER SAME. BPE MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF MERCHANTABILITY.  

  

	3.4.	BPE shall be responsible for obtaining all raw materials required for the manufacture of PRODUCT hereunder. BPE shall use its commercially reasonable efforts to deliver PRODUCT to
ACADIA on the agreed upon delivery dates. BPE shall supply the PRODUCTS to ACADIA together with a certificate of analysis (“COA”) confirming that such PRODUCT meets the specifications set forth in the relevant
PRODUCT schedule and was manufactured in accordance with cGMP and such additional documentation as detailed in the Quality Agreement. ACADIA shall inspect each delivery of PRODUCT to confirm that it meets the specifications.
ACADIA may reject PRODUCT that does not conform to the warranties in Section 3.2. IN ORDER TO REJECT PRODUCT, ACADIA MUST GIVE WRITTEN NOTICE TO BPE OF SUCH REJECTION WITHIN [...***...] DAYS AFTER DELIVERY OF PRODUCT AND, IN THE EVENT OF DEFECTS WHICH CANNOT BE DETECTED UPON DILIGENT INSPECTION (“LATENT DEFECT”), WITHIN [...***...] DAYS AFTER DETECTION OF A LATENT
DEFECT. ACADIA’s FAILURE TO GIVE SUCH NOTICE TO BPE OF ANY CLAIM WITHIN [...***...] DAYS AFTER THE DATE OF DELIVERY OR [...***...] DAYS AFTER DETECTION OF A LATENT DEFECT, AS APPLICABLE, SHALL CONSTITUTE ACCEPTANCE OF THE PRODUCT.
If notice of rejection is given, ACADIA shall cooperate with BPE in determining whether rejection is necessary or justified. BPE will evaluate process issues and other reasons for such non-compliance. If BPE in good faith
disagrees with ACADIA’s determination that PRODUCT does not meet the warranties in Section 3.2, it shall provide written notice to ACADIA within [...***...] days after notice of rejection from ACADIA (and
BPE shall be deemed to accept such rejection if it does not provide notice within such period). If the Parties fail to reach agreement on the matter within [...***...] days after BPE’s notice to ACADIA of
disagreement with the notice of rejection, then as promptly as practicable, and in any event within [...***...] days after ACADIA receives BPE’s notice of disagreement, such PRODUCT and the applicable COA shall (i)
with respect to a dispute regarding compliance with specifications, be submitted to a mutually acceptable third party laboratory which shall determine whether such PRODUCT meets the specifications and (ii) with respect to a dispute
regarding cGMP compliance, be submitted to a mutually acceptable third party quality/regulatory consultant. The Parties 

  
 ***Confidential
Treatment Requested 
  
 3 

	 	
shall cooperate with the third party’s reasonable requests for assistance in connection with its analysis and agree that such applicable third party’s determination shall be final and
binding on each of the Parties. The Party against whom the third party rules shall bear all costs of the third party testing/services. Whether or not BPE accepts ACADIA’s rejection of PRODUCT, BPE shall endeavour to
replace any PRODUCT for which ACADIA has provided a notice of rejection with PRODUCT that complies with the warranties set forth in Section 3.2 as promptly as practicable, but in any event, within [...***...] days from the date the notice of rejection is provided. If ACADIA’s rejection of PRODUCT is accepted or deemed accepted by BPE or confirmed by the determination of the
third party, then BPE shall bear the cost of the replacement PRODUCT. If the third party determination does not confirm ACADIA’s rejection of PRODUCT, then ACADIA shall bear the cost of any replacement
PRODUCT along with the cost of rejected PRODUCT if ACADIA has not previously paid for such PRODUCT. If the PRODUCT is not replaced within such [...***...]-day period described above, and ACADIA’s
rejection of PRODUCT is accepted or deemed accepted by BPE or confirmed by the determination of the third party, BPE shall refund the amount paid by ACADIA, on a pro rata basis, for the portion of the PRODUCT that
is not replaced. For clarity, the foregoing sentence shall not limit BPE’s obligations to replace such PRODUCT. The rights and obligations in this Section 3.4 with respect to any PRODUCT shall continue during the term
of the Agreement. 

  

	3.5.	Any modification of the production process of the PRODUCT, or materials, equipment, or procedures used to manufacture PRODUCT [...***...] may only be carried out by BPE or its Affiliates with
prior written consent of ACADIA and in accordance with the quality agreement between the Parties. 

  

	3.6.	BPE shall keep and shall ensure that its Affiliates keep complete, accurate, up-to-date, and authentic accounts, notes, data and records of the work performed under this Agreement. Upon ACADIA’s
written request, BPE shall allow ACADIA to review such records for the purposes of assuring PRODUCT quality and compliance with cGMP. ACADIA acknowledges that all manufacturing records shall be protected under the
confidentiality provisions of Section 7. BPE shall have and maintain, or shall procure that its Affiliates have and maintain, during the term of this Agreement all government permits and licenses, including without limitation health,
safety and environmental permits, necessary for the conduct of the activities that it undertakes pursuant to this Agreement. BPE shall use commercially reasonable efforts to assist ACADIA in obtaining regulatory approval of any
pharmaceutical product containing PRODUCT. BPE shall, and shall ensure that its Affiliates, as applicable, agree to reasonably cooperate with any inspection by any regulatory authority. ACADIA will reimburse BPE for its (or its
Affiliates) out-of-pocket costs incurred in connection with any such assistance and cooperation provided under this Section 3.6. 

  
 ***Confidential
Treatment Requested 
  
 4 

	4.	Price and Payment terms 

  

	4.1	The price is agreed for each PRODUCT in the relevant PRODUCT schedule. 

  

	4.2.	The delivery terms for each PRODUCT are agreed upon in the relevant PRODUCT schedule. Risk of loss of, and title to, PRODUCT transfers to ACADIA when the PRODUCT has been delivered in accordance with the agreed
upon INCOTERM. 

  

	4.3.	Payment for the amount of PRODUCT actually delivered has to be made after delivery of the applicable PRODUCT and delivery of all documentation to be delivered with respect to the applicable PRODUCT under the Quality
Agreement and within [...***...] days net from the date of the written invoice to ACADIA (which invoice will be provided on or after delivery of the applicable PRODUCT and
documentation), unless the PRODUCT is rejected by ACADIA in good faith within [...***...] days from the date of delivery, provided that, if BPE disagrees in good faith with ACADIA’s rejection, payment shall still be required by ACADIA
within [...***...] days after ACADIA’s receipt of BPE’s notice of disagreement. If the applicable COA is not provided with (or prior to the delivery of) the PRODUCT, ACADIA will promptly notify BPE and BPE will send ACADIA the COA.

  

	5.	Termination / Cancellations 

  

	5.1.	This Agreement or any of the PRODUCT schedules may be terminated in accordance with the stipulations set forth in Sections 5.2 and 5.3. If ACADIA wishes to terminate this Agreement or a PRODUCT schedule,
ACADIA agrees to pay BPE all amounts owing to BPE to the date of termination in accordance with the other provisions of this Agreement and the PRODUCT schedules [...***...]. 

 

	5.2.	This Agreement or any of the PRODUCT schedules may be terminated immediately by a Party upon written notice to the other Party: 

  

	 	5.2.1.	in the event of a material breach of this Agreement by the other Party where such breach is capable of cure and such breach remains uncured [...***...] days after notice of such breach; or 

 

	 	5.2.2.	if the other Party shall dissolve or liquidate, or if the other Party shall make an assignment for the benefit of its creditors. 

  

	5.3.	If ACADIA, including its affiliates, ceases the development, marketing and sales of the end product processed from a PRODUCT, the relevant PRODUCT schedule may be terminated promptly upon written notice
from ACADIA. In addition, ACADIA may terminate this Agreement or any PRODUCT schedule upon at least 3 months’ prior written notice to BPE. In case of termination under this Section 5.3, [...***...].

  
 ***Confidential
Treatment Requested 
  
 5 

	5.4.	All notices required or permitted hereunder, including notices of termination, shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the Party to be notified, (b) when sent
by confirmed email, telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. The addresses for such communications are: 

If to ACADIA: 
 ACADIA
Pharmaceuticals GmbH 
 Pilatusstrasse 41 

6003 Lucerne 
 Switzerland 

Facsimile: [...***...] 

E-mail: [...***...] 

Attn: [...***...] 
 cc:

 ACADIA Pharmaceuticals Inc. 

3611 Valley Centre Drive, Suite 300 

San Diego, CA 92130 
 Facsimile:
[...***...] 
 E-mail: [...***...] 

Attn: [...***...] 
 If to
BPE: 
 BASF Pharma (Evionnaz) SA 

CH- 1902 Evionnaz (VS) 
 1,
Route du Simplon 
 Facsimile: [...***...] 

Attn: [...***...] 

E-mail: [...***...] 
 cc:
BASF SE 
 ZRR – D 100 

Carl-Bosch-Str. 38 
 67056
Ludwigshafen, Germany 
 Attn: [...***...] 

Facsimile: [...***...] 

  
 ***Confidential
Treatment Requested 
  
 6 

	6.	Liability; Allocation and Force Majeure 

 6.1 Liability 

 

	6.1.1.	BPE shall indemnify ACADIA and its affiliates and its and their respective directors, officers and employees from and against any and all liabilities, expenses and/or losses, including reasonable legal
expenses and reasonable attorneys’ fees (“Losses”), incurred by any such indemnified party as a result of any third party claim, demand, action or other proceeding (“Claim”) resulting from or arising out of (i) the
[...***...] of [...***...], (ii) a [...***...] of [...***...], or (iii) the [...***...] of [...***...], except, in each case, to the extent
that a Claim results from or arises out of (a) the negligence or willful misconduct of ACADIA, or (b) a breach of ACADIA’s obligations, representations, or warranties. 

 

	6.1.2.	ACADIA shall indemnify BPE and its Affiliates and its and their respective directors, officers and employees from and against any and all Losses incurred by any such indemnified party as a result of any
Claim resulting from or arising out of (i) the [...***...] of [...***...], (ii) a [...***...] of [...***...], or (iii) the [...***...] of [...***...], except, in each case, to the extent that a
Claim results from or arises out of (a) the negligence or willful misconduct of BPE, or (b) a breach of BPE’s obligations, representations, or warranties. 

 

	6.1.3.	A party entitled to indemnification under this Section 6 shall give written notice to the indemnifying party of any Claim that may be subject to indemnification promptly after learning of such Claim, and the
indemnifying party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed by the indemnifying party with counsel so selected, the indemnifying party will not be subject to any
liability for any settlement of such Claim made by the indemnified party without the indemnifying party’s consent (but such consent will not be unreasonably withheld or delayed), and will not be obligated to pay the fees and expenses of any
separate counsel retained by the indemnified party with respect to such Claim. 

  

	6.1.4.	NOTWITHSTANDING ANY OTHER LANGUAGE HEREIN, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY RIGHTS OR
OBLIGATIONS HEREUNDER; provided, however, that this Section 6.1.4 shall not be construed to limit either party’s indemnification obligations under Section 6.1.1 or 6.1.2 or liability for breach of Section 7. 

  
 ***Confidential
Treatment Requested 
  
 7 

	6.1.5.	Except for any liability arising from gross negligence or wilful misconduct, to the fullest extent permitted by law, and notwithstanding any other provision of this Agreement, BPE’s total liability, in the
aggregate, for any and all claims and losses occurring in a particular calendar year, including without limitation, attorneys’ fees and costs of any nature whatsoever or expenses, resulting from or in any way related to this Agreement from any
cause or causes shall not exceed [...***...]. Notwithstanding the foregoing, (a) in no event shall this Section 6.1.5 apply to liability for breach of Section 7; and (b) with respect
to BPE’s indemnification obligations under 6.1.1, BPE’s total liability, in the aggregate, for any and all claims and losses occurring in a particular calendar year shall not exceed [...***...]or [...***...], whichever is
greater. 

  

	6.1.6.	Liability for non-conforming Product. 

  

	 	a)	THE LIABILITY OF BPE FOR THE DELIVERY OF PRODUCT NOT COMPLIANT WITH THE WARRANTIES IN SECTION 3.2 (HEREINAFTER “NON-CONFORMING PRODUCT”) SHALL BE LIMITED TO THE REPLACEMENT OF THE NON-CONFORMING PRODUCT WITH
PRODUCT THAT COMPLIES WITH THE WARRANTIES IN SECTION 3.2 IN ACCORDANCE WITH SECTION 3.4. 

  

	 	b)	BPE shall bear full manufacturing cost of such replacement, including (i) the purchasing cost of raw materials and (ii) the cost of destruction of any Non-Conforming Product. 

 

	 	c)	IN THE EVENT THAT BPE IS NOT ABLE TO REPLACE NON-CONFORMING PRODUCT IN ACCORDANCE WITH SECTION 3.4, THEN BPE’S LIABILITY FOR NON-CONFORMING PRODUCTS SHALL BE LIMITED TO REFUNDING THE CONSIDERATION RECEIVED FOR THE
NON-CONFORMING PRODUCT DELIVERED IN ACCORDANCE WITH SECTION 3.4. 

  
 ***Confidential
Treatment Requested 
  
 8 

	6.2	Force Majeure 

  

	6.2.1	Any events and circumstances whose occurrence is beyond the reasonable control of the Parties, such as acts of nature, war, labour disputes, industry-wide shortages of raw materials (that affect suppliers generally and
not just BPE) or shortages of power, unavoidable transport and plant stoppages, fire or explosion, order of authority – including where such events make performance of the affected business uneconomical for the foreseeable future –shall
discharge the affected Party from liability for failure or delay in performance under this Agreement for the period of interruption and to the extent of their effects from its obligations under this Agreement. Such discharge shall be effective only
to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. In a case of force majeure, BPE is not obliged to buy in PRODUCT for delivery from third
parties. 

  

	6.2.2	The affected Party shall promptly notify the other Party of the anticipated duration and extent of the interruption and shall take all reasonable measures to forthwith remedy the interruption. The affected Party shall
make reasonable efforts to make good non-performed services within its capacity. 

  

	6.2.3	Notwithstanding the foregoing, in the event a force majeure event results in a delay or failure in performance by BPE of any of its obligations under this Agreement for a period of [...***...] days or more, ACADIA shall have the right to terminate this Agreement immediately upon written notice to BPE [...***...]. 

 

	7.	Confidentiality 

  

	7.1	 The Parties agree that a Party (hereinafter the receiving party) receiving Confidential Information (defined below) of the other Party
(hereinafter the disclosing party) will (i) maintain in confidence such Confidential Information to the same extent the receiving party maintains its own proprietary information of similar kind and value (but at a minimum the
receiving party shall use commercially reasonable efforts to maintain Confidential Information of the disclosing party in confidence), (ii) not disclose such Confidential Information to any third party without prior written
consent of the disclosing party, except in the case of ACADIA for disclosures made in confidence to any permitted sub licensees or other strategic partners or in connection with financings and (iii) not use Confidential Information of
the disclosing party for any purpose except those permitted by this Agreement. However, ACADIA may disclose Confidential Information received from BPE to the appropriate regulatory authorities in connection with obtaining
regulatory approval of products containing or based on PRODUCT. Each Party may disclose the Confidential Information to its affiliates and its permitted subcontractors who have a need to know such information for purposes of this Agreement,
provided that such affiliates and permitted subcontractors are bound by obligations of confidentiality and non-use consistent with those set forth in this Agreement. Each Party shall remain liable to the other

  
 ***Confidential
Treatment Requested 
  
 9 

 
Party for compliance of its affiliates and permitted subcontractors with the provisions of this Section 7. 

Confidential Information of a disclosing party shall mean all confidential or proprietary information of such Party, whether in written form or disclosed
orally, visually and/or in other form, disclosed by such Party or any of its affiliates or its or its affiliates’ representatives to the receiving party or any of its affiliates. For purposes of clarification, all material and information
disclosed by ACADIA to BPE that directly and specifically relates to PRODUCT and all data generated as a result of the manufacture of the PRODUCT to the extent they exclusively relate to PRODUCT (including, without
limitation, all non-severable improvements, as defined below), shall be included within the Confidential Information of ACADIA. The receiving party shall have no obligation under this Section 7 with respect to any Confidential
Information of the other party which the receiving party can demonstrate by competent proof: 
  

	 	a)	is in the public domain at the time of disclosure; 

  

	 	b)	is published or otherwise becomes part of the public domain through no fault of the receiving party; 

  

	 	c)	is known to the receiving party, before receipt thereof under this Agreement; 

  

	 	d)	is disclosed to the receiving party without restriction by a third party who has the right to disclose it to the receiving party; or 

 

	 	e)	has been developed independently by the receiving party, without the use of the disclosing party’s Confidential Information. 

Disclosure of Confidential Information of the disclosing party shall not be precluded to the extent such disclosure is in response to a
valid order of a court or other governmental body or is required by law or regulation; provided, however, that the receiving party shall first give reasonable prior notice to the disclosing party and thereafter shall cooperate
with the disclosing party’s efforts, if applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the Confidential Information so disclosed be used only for the purposes for which such order was
issued or as required by such law or regulation. Any Confidential Information so disclosed shall still remain subject to the obligations of this Section 7. 
  

	7.2.	This confidentiality obligation will continue for a period of [...***...] years after the termination or expiration date of this Agreement. Neither of
the Parties shall be required to disclose to the other Party any information known to be property of, or obtained under obligations of secrecy from a third party. 

 

	7.3	The Confidential Information shall be deemed the property of the disclosing party and, upon request, the receiving party will, at the disclosing party’s option, either return all Confidential Information in
tangible form or destroy all such Confidential Information and certify such destruction in writing to the 

  
 ***Confidential
Treatment Requested 
  
 10 

	 	
disclosing party. The receiving party is entitled to keep one set of copies of the disclosing party’s Confidential Information for archival purposes in its legal department. The receiving
party shall not obtain, and shall not attempt to obtain, patent coverage or any other sort of proprietary right on the received Confidential Information or on any invention, substance, or process that could not have been made but for knowledge of
the received Confidential Information. Neither Party shall be deemed by this Agreement to have granted to the other Party any right or license under any patent application, issued patent, know-how or other proprietary information of such Party.

  

	7.4	Except as otherwise provided in this Article 7, each Party agrees not to disclose to any third party the existence of this Agreement or the terms of this Agreement without the prior written consent of the other Party
hereto, except that each Party may disclose the terms of this Agreement that are not otherwise made public as contemplated by this Section 7.4 as permitted under Section 7.1. Additionally, ACADIA shall have the right, upon consultation
with BPE, to issue press releases relating to future events occurring in connection with this Agreement as reasonable determined by ACADIA; subject to ACADIA’s confidentiality obligations with respect to BPE’s Confidential Information as
set forth above. Each Party shall have the right to disclose the terms of this Agreement and any PRODUCT schedules as required by applicable laws and regulations including disclosure requirements of the U.S. Securities and Exchange Commission
(“SEC”) or any stock exchange on which securities issued by ACADIA or its affiliates are traded. The Parties will coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain
provisions of this Agreement) with the SEC or any stock exchange on which securities issued by a Party or its affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted;
provided that each Party will ultimately retain control over what information to disclose to the SEC or any stock exchange as the case may be. 

For the avoidance of doubt, ACADIA shall at all times remain the sole and exclusive owner of all right, title and interest in and to the PRODUCT
(including, without limitation, all intellectual property rights claiming the PRODUCT or its manufacture, use or sale). The Parties agree that ACADIA shall be the sole and exclusive owner of any ideas, discoveries, inventions,
improvements, innovations and the like (whether or not patentable) developed by BPE or any of its Affiliates during the term of this Agreement to the extent relating to the PRODUCT [...***...] (“non-severable improvements”) and BPE hereby transfers and assigns to ACADIA all right, title and interest in and to the non-severable improvements.
ACADIA may obtain patent, copyright, and/or other proprietary protection respecting the same non-severable improvements, subject to the terms and conditions of this Agreement. At the reasonable request and expense of ACADIA,
BPE shall, and shall procure that its Affiliates, at ACADIA’s cost, take all actions and execute all documents necessary to transfer, effect, confirm, perfect, record, preserve, protect and enforce ACADIA’s rights in
all rights, title and interests transferred hereunder. BPE hereby grants, and shall procure that its Affiliates 

  
 ***Confidential
Treatment Requested 
  
 11 

 
grant, ACADIA a non-exclusive, worldwide, perpetual, irrevocable, royalty free license, without the right to sublicense, to use ideas, discoveries, inventions, improvements, innovations and the
like (whether or not patentable) developed during the term of this Agreement to the extent relating to the PRODUCT [...***...] (“severable improvements”) developed by
BPE or its Affiliates during the term of this Agreement for the purpose of the manufacture of PRODUCT. Additionally, ACADIA has the right to allow a third party manufacturer to make the PRODUCT using those severable improvements developed by
BPE or its Affiliates, provided ACADIA notifies BPE of any such manufacturer. 
  

	8.	Duration of the Agreement 

  

	8.1	This Agreement shall commence on August 17, 2015 (the “Effective Date”) and shall continue in full force and effect until the end of the fifth full calendar year following the Effective Date (the
“Initial Term”). After the Initial Term, the Agreement shall automatically be renewed for successive terms of one (1) year each (the “Renewed Term”). This Agreement may be terminated at the end of the Initial Term or any
Renewed Term by the provision of notice in writing from one Party to the other, without having to assign any reasons therefore, which notice shall not be given less than twelve (12) months prior to the end of the Initial Term or the relevant
Renewed Term. Each Party may terminate this Agreement or a PRODUCT schedule early as provided in Section 5. 

  

	8.2	Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. The provisions of Sections 3.3, 3.6, 5, 6, 7, 8 and 9 shall survive any
termination or expiration of this Agreement. 

  

	9.	Applicable Law; Miscellaneous 

  

	9.1.	This Agreement shall be governed by the substantive laws of Switzerland excluding (i) its renvoi provisions on the conflict of laws and (ii) the United Nations Convention on Contracts for International Sale of
Goods. Any dispute, controversy or claim, arising out of or in relation to this Agreement, including the validity, invalidity, breach or termination thereof, shall be resolved by arbitration in accordance with the Swiss Rules of International
Arbitration of the Swiss Chambers of Commerce in force on the date when the Notice of Arbitration is submitted in accordance with these Rules. The number of arbitrators shall be one. The seat of arbitration shall be [...***...]. The arbitral
proceedings shall be conducted in English. 

  

	9.2.	This Agreement shall not be assignable by either Party without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed, except that either Party may make such an assignment
without the other Party’s consent to an affiliate or to a successor to 

  
 ***Confidential
Treatment Requested 
  
 12 

	 	
substantially all of its business to which this Agreement relates, whether in merger, sale of stock, sale of assets or other transaction; provided that with regard to any such transfer to an
affiliate, the transferring party will continue to remain liable under this Agreement. This Agreement shall be binding upon and inure to the benefit of the Parties’ successors, legal representatives and permitted assigns. 

 

	9.3	No amendment, modification or waiver of any terms or conditions hereof shall be effective unless made in writing and signed by a duly authorized representative of each Party. In the event of any conflict between this
Agreement or the PRODUCT schedule and the Quality Agreement, the Quality Agreement shall control with respect to quality-related matters, and this Agreement and the PRODUCT schedule, as applicable, shall control with respect to all other matters.

  

	9.4	The failure of a Party in any one or more instances to insist upon strict performance of any of the terms and conditions of this Agreement shall not constitute a waiver or relinquishment, to any extent, of the right to
assert or rely upon any such terms or conditions on any future occasion. 

  

	9.5	This Agreement (including all exhibits and schedules hereto) embodies the entire, final and complete agreement and understanding between the Parties and replaces and supersedes all prior discussions and agreements
between them with respect to the specific subject matter covered hereby. 

  

	9.6	ACADIA acknowledges that BPE has no control over ACADIA’s use or disposition of, or its subsequent processing or admixing of any PRODUCT with other chemicals or materials subsequent to delivery of PRODUCT, and
ACADIA assumes the liability and responsibility therefor. 

  

	9.7	BPE shall remain responsible for the performance by its Affiliates of any of its obligations under this Agreement. 

  

	9.8	This Agreement may be executed in counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties or their representative legal counsel, each of which shall be deemed an original
document, and all of which, together with this writing, shall be deemed one instrument. The Parties additionally agree to exchange hard copy signature pages of the Agreement promptly following execution. 

 

	9.9	 BPE represents and warrants that it shall not employ, contract with, or retain any person directly or indirectly to perform any services under this
Agreement if such a person (a) is under investigation by the U.S. Food and Drug Administration (“FDA”) for debarment or is presently debarred by the FDA pursuant to 21 U.S.C. § 335a or its successor provisions, or (b) has a
disqualification hearing pending or has been disqualified by the FDA pursuant to 21 C.F.R. § 312.70 or its successor provisions. In addition, BPE represents and warrants that it has not engaged in any conduct or activity which could lead to any
of the above-mentioned disqualification or debarment actions. If, during the term of this Agreement, BPE or any person employed or retained by it to perform under this Agreement (i) comes under investigation by the FDA

  
 13 

	 	
for a debarment action or disqualification, (ii) is debarred or disqualified, or (iii) engages in any conduct or activity that could lead to any of the above-mentioned disqualification
or debarment actions, BPE shall immediately notify ACADIA of same. 

 IN WITNESS WHEREOF, the Parties sign, through their authorized
representatives, have executed this Agreement in three original sets as of the dates set forth below. 
  

									
	ACADIA Pharmaceuticals GmbH	 		 	BASF Pharma (Evionnaz) SA
					
	By:	 	/s/ Glenn F. Baity	 		 	By:	 	/s/ Daniel Lasanow
	Name:	 	Glenn F. Baity	 		 	Name:	 	Daniel Lasanow
	Title:	 	Director	 		 	Title:	 	Managing Director
			
	Date: 17 August 2015	 		 	Date: 17 August 2015

  
 14 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 Page 1 of 6

 PRODUCT SCHEDULE No 1. 

(FOR SUPPLY OF Pimavanserin) 
 to the
Co-operation Agreement with effective date August 17, 2015 entered into between: 
  

	(1)	ACADIA Pharmaceuticals GmbH, (“ACADIA”); and 

  

	(2)	BASF Pharma (Evionnaz) SA, (“BPE”) 

 (the “Agreement”) 

This Product Schedule is made pursuant to, and is subject to all of the terms and conditions contained in the Agreement. Together, this Product Schedule and
the Agreement form a binding agreement between the Parties in relation to the details set out in this Product Schedule. 
 This Product Schedule consists of
the following parts: 
  

							
	 1.
	 	 PART A: Product, Specifications and Manufacturing Program
	  	 	2	  
			
	 2.
	 	 PART B: Delivery, Forecasting, Orders and Lead Times
	  	 	2	  
			
	 3.
	 	 PART C: Pricing and Payment
	  	 	3	  
			
	 4.
	 	 PART D: Special Conditions in addition to the Agreement
	  	 	4	  
			
	 5.
	 	 PART E: Term of Product Schedule
	  	 	5	  

 Page 2 of 6 
  

	1.	PART A: Product, Specifications and Manufacturing Program 

  

	1.1	Product: Pimavanserin 

 Product Specifications: The PRODUCT specifications have
been separately provided by ACADIA to BPE. The PRODUCT specifications may be updated from time to time as agreed by the Parties. 

Production Site: BASF Pharma (Evionnaz) SA 

Manufacturing Program: Commercial 
  

	2.	PART B: Delivery, Forecasting, Minimum Orders, Orders and Lead Times 

  

	2.1	Delivery Terms (Incoterms 2010): FCA BASF Pharma (Evionnaz) SA facility 

 2.1.1
Deliverables required to be included with PRODUCT supplied by BPE are described in the quality agreement executed by the Parties. 
  

	2.2	Forecasting: 

 By the [...***...] day
of the last month in a given calendar quarter (or by the immediately preceding business day if the [...***...] day of the month is not a business day), ACADIA shall provide BPE with a rolling forecast which will state: (1) the required
amounts and delivery dates of the PRODUCT in each month for the immediately subsequent [...***...] month period (the “Initial [...***...] Month Period”) and (2) a quarterly estimate of the required amounts for each of the
[...***...] quarters following the Initial [...***...] Month Period (such quarterly estimate shall be updated only every [...***...] months) (“Rolling Forecast”). The amount of the PRODUCT stated for the first
[...***...] months of each Rolling Forecast (“Binding Part”) shall be binding upon both ACADIA and BPE, and the subsequent quarterly estimates of each Rolling Forecast shall be non-binding and for the purpose of reference only. 

ACADIA is aware that in case of orders in a [...***...] month period over [...***...], a new batch size shall have to be revalidated. 

 

	2.3	Minimum Orders 

 There will be no minimum quantity of PRODUCT to be ordered yearly. Each Firm PO (as
defined below) shall however provide a minimum quantity equal to no less than [...***...] of the validated batch size of the final process step ([...***...]). The current batch size is approximately [...***...]. 

  
 *** Confidential
Treatment Requested 

 Page 3 of 6 
  

	2.5	Lead Times: 

 In accordance with the Binding Part set forth on the applicable Rolling Forecast,
ACADIA shall deliver firm purchase orders for the PRODUCT to BPE at least [...***...] prior to the requested delivery date(s) of the PRODUCT to ACADIA (the “Firm POs”). Such
Firm POs shall specify at a minimum: (i) the quantity of required PRODUCTS, (ii) the requested delivery dates for such specified quantities, and, (iii) the place of delivery. Upon receipt of such Firm POs, BPE shall promptly
acknowledge such receipt in writing. BPE shall supply all PRODUCTS ordered in Firm POs in accordance with this Agreement and the Firm PO. Should ACADIA order a quantity in excess of the forecasted amount in the Binding Part of a Rolling Forecast,
BPE shall use its commercially reasonable efforts to meet ACADIA’s demand that exceeds the forecasted amount. ACADIA shall not have any recourse to BPE, and BPE shall not be liable to ACADIA in the event the demand above the forecasted quantity
in the Binding Part of a Rolling Forecast cannot be produced in the time requested. 
  

	3.	PART C: Pricing and Payment 

  

	3.1	Price 

 [...***...] 

All PRODUCT prices as set forth in the table above (“Prices”) are calculated based on volume of PRODUCT ordered in each Firm PO. 

All Prices shall be [...***...], and any [...***...]. 

At either Party’s request, BPE and ACADIA will jointly review cost saving factors at the end of each calendar year, in relation to
BPE’s or ACADIA’s investments and 

  
 *** Confidential
Treatment Requested 

 Page 4 of 6 
  

 
make any necessary adjustments to the price with regard to the benefits coming from such cost savings. In principle, any cost saving arising out of any investment made by a Party shall be passed
along to the Party responsible for cost savings. 
 In the event of any substantial increase [...***...] in the manufacturing cost of the PRODUCT, such as prices of raw materials, energy or utilities, the Parties shall[...***...] forthwith meet and negotiate in good faith to mutually agree on a
revision to the Price consistent with the substantial increase in manufacturing cost of the PRODUCT. BPE agrees to provide supporting information and documentation as reasonably requested by ACADIA to evidence such substantial increase in
manufacturing costs. BPE shall have the right to request negotiations as described in this paragraph no more than once per calendar year during the term of this PRODUCT Schedule. The parties will both use commercially reasonable efforts to reach
agreement on the revision to the Price within [...***...] after receipt by ACADIA of the request and such information and documentation. 
  

	3.2	Invoice Currency 

 CHF 

Bank account: 
 Payment
shall be made to account stated on the invoice. Invoices shall be paid in accordance with the terms set forth in the Agreement, notwithstanding anything to the contrary indicated on the invoice provided. 

 

	4.	PART D: [...***...] Special Conditions in addition to the Agreement 

 If ACADIA
terminates the Agreement or this Product Schedule other than in accordance with Section 5.2 or Section 6.2.3 of the Agreement, then ACADIA shall pay [...***...] the out-of-pocket cost of all purchased and non-returnable or refundable
raw-materials purchased before BPE’s receipt of ACADIA’s notice of termination [...***....] 

  
 *** Confidential
Treatment Requested 

 Page 5 of 6 
  

 [...***...] 

If ACADIA is [...***...], BPE shall [...***...] in accordance with this PRODUCT schedule and the Agreement [...***...]. 

 

	5.	PART E: Term of Product Schedule 

 This Product Schedule shall commence on August 17, 2015 (the
“Effective Date”) and shall continue in full force and effect until the end of the fifth full calendar year following the Effective Date (the “Initial Term”). After the Initial Term, the Product Schedule shall automatically be
renewed for successive terms of one (1) year each (the “Renewed Term”). This Product Schedule may be terminated at the end of the Initial Term or any Renewed Term by the provision of notice in writing from one Party to the other, without
having to assign any reasons therefore, which notice shall not be given less than six (6) months prior to the end of the Initial Term or the relevant Renewed Term. The Product Schedule may be terminated earlier subject to and in accordance with the
terms and conditions contained in the Agreement. 

  
 *** Confidential
Treatment Requested 

 Page 6 of 6 
  

 Execution 

THIS PRODUCT SCHEDULE IS EXECUTED by the authorised representatives of the Parties as of the date last written below. 

 

									
	SIGNED for and on behalf of	 		 	SIGNED for and on behalf of
	ACADIA Pharmaceuticals GmbH	 		 	BASF Pharma (Evionnaz) SA
			
	 /s/ Glenn F. Baity
	 		 	 /s/ Daniel Lasanow

	Signature	 		 	Signature
					
	Name:	 	Glenn F. Baity	 		 	Name:	 	Daniel Lasanow
	Title:	 	Director	 		 	Title:	 	Managing Director
					
	Date:	 	17 August 2015	 		 	Date:	 	17 August 2015Exhibit

FOURTH AMENDMENT, CONSENT AND RELEASE
TO
AMENDED AND RESTATED CREDIT AGREEMENT

THIS FOURTH AMENDMENT, CONSENT AND RELEASE TO AMENDED AND RESTATED CREDIT AGREEMENT (this "Amendment") is entered into as of November 2, 2015, by and among Wells Fargo BANK, NATIONAL ASSOCIATION, as agent ("Agent") for the Lenders (as defined in the Credit Agreement referred to below), the Lenders party hereto, and NUVERRA ENVIRONMENTAL SOLUTIONS, INC., a Delaware corporation ("Borrower").
WHEREAS, Borrower, Agent, and Lenders are parties to that certain Amended and Restated Credit Agreement dated as of February 3, 2014 (as amended, restated, modified or supplemented from time to time, the "Credit Agreement");
WHEREAS, to guarantee and secure payment and performance of the Obligations under the Credit Agreement, Borrower, the Guarantors party thereto (the "Guarantors" together with Borrower, the "Original Loan Parties") and Agent entered into that certain Amended and Restated Guaranty and Security Agreement, dated as of February 3, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), pursuant to which each Guarantor guaranteed the Obligations and each Loan Party granted to Agent, for the benefit of the Lenders, a security interest in substantially all of each Loan Party's assets;
WHEREAS, Borrower owns all of the issued and outstanding Equity Interests of Nuverra Rocky Mountain Pipeline, LLC, a Delaware limited liability company (together with any direct or indirect subsidiaries thereof, "Nuverra Rocky Mountain");
WHEREAS, the Loan Parties have notified Agent and the Lenders that Borrower and/or another Loan Party desire to enter into a joint venture agreement (the "JV Agreement"), pursuant to which Borrower may either sell, transfer and convey substantially all of the Equity Interests of Nuverra Rocky Mountain, or permit Nuverra Rocky Mountain to issue Equity Interests to, a third party investor in such joint venture; 
WHEREAS, the Loan Parties have requested that Agent and the Lenders each: (i) consent to the issuance, sale, transfer, conveyance or other disposition (collectively, as used herein, the "disposition") of the Equity Interests of Nuverra Rocky Mountain in connection with such Loan Party's entry into the JV Agreement; (ii) release Agent's Lien on the assets of Nuverra Rocky Mountain; and (iii) release Nuverra Rocky Mountain from its obligations under the Security Agreement and each other Loan Document;
WHEREAS, Agent and Lenders are each willing to provide such consent and release on the terms as set forth herein; and
WHEREAS, Agent, Lenders and Borrower have agreed to amend the Credit Agreement in certain respects.
NOW THEREFORE, in consideration of the premises and mutual agreements herein contained, the parties hereto agree as follows:
1.Defined Terms.  Unless otherwise defined herein, capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Credit Agreement.

2.Consent and Release.  In reliance upon the representations and warranties of Borrower set forth in Section 7 below and subject to the satisfaction of the conditions to effectiveness set forth in Section 6 below, Agent and Lenders consent to the disposition of the Equity Interests of Nuverra Rocky Mountain in connection with the Borrower's and/or another Loan Party's entry into the JV Agreement, and acknowledge, confirm and agree that (x) Nuverra Rocky Mountain is released from all Obligations under the Security Agreement and each other Loan Document, (y) Nuverra Rocky Mountain shall no longer be, or be deemed to be, a "Guarantor", "Grantor", "Loan Party" or obligor of any nature under or pursuant to the Security Agreement or any other Loan Document, and (z) Agent's Liens on all the assets of Nuverra Rocky Mountain are released.  Upon the disposition of the Equity Interests of Nuverra Rocky Mountain pursuant to the terms of the JV Agreement, Agent and Lenders acknowledge, confirm and agree that Agent's Lien on the portion of the Equity Interests of Nuverra Rocky Mountain subject to such disposition (the "Transferred Shares"; for the avoidance of doubt, in no event shall the Transferred Shares include any Equity Interests of Nuverra Rocky Mountain owned by Borrower or any Loan Party after the consummation of such disposition) is automatically released.  This consent is a limited consent and shall not be deemed to constitute a consent with respect to any other current or future departure from the requirements of any provision of the Credit Agreement or any other Loan Documents.  Upon the effectiveness of the consent set forth in this Section 2, (i) Agent agrees to promptly deliver to the Borrower, Nuverra Rocky Mountain or their respective designees (as directed by Borrower) (A) such UCC-3 termination statements, terminations, releases, or other documents necessary or reasonably required to effect such release, and (B) such certificates or other instruments representing the assets owned by Nuverra Rocky Mountain, and (ii) Agent authorizes the Borrower, Nuverra Rocky Mountain and/or their respective designees to file UCC-3 termination statements effecting the foregoing.  Upon delivery of the executed JV Agreement pursuant to Section 9 below, Agent agrees to promptly deliver to Borrower such certificates or other instruments representing the Transferred Shares.

3.Amendments to Credit Agreement.  In reliance upon the representations and warranties of Borrower set forth in Section 7 below, and subject to the satisfaction of the conditions to effectiveness set forth in Section 6 below, the Credit Agreement is hereby amended as follows:

(a)Section 2.1(c) of the Credit Agreement is hereby amended to insert a new sentence at the end thereof to read in its entirety as follows: "Without limiting the foregoing, Agent shall establish the Interest Payment Reserves, Appraisal Reserves and the Pipeline Reserves."

(b)Section 2.4(e)(ii) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

(ii)    Dispositions.  
(1) Within 3 Business Days of the date of receipt (or if an Activation Instruction (as defined in the Guaranty and Security Agreement) is in effect concurrently with receipt) by Borrower or any of its Subsidiaries of the Net Cash Proceeds of any voluntary or involuntary sale or disposition by Borrower or any of its Subsidiaries of any Accounts or Equipment (including casualty losses or condemnations) in excess of $1,000,000 in the aggregate (calculated as an amount equal to the lesser of (x) 100% of the Net Cash Proceeds (including condemnation awards and payments in lieu thereof) received by such Person in connection with such sales or dispositions, or (y) 100% of the Net Orderly Liquidation Value of such Accounts and/or Equipment at such time identified in the most recent appraisal ordered and obtained by Agent subject to such sale or disposition) for all such sales 

-2-

and dispositions of Accounts and/or Equipment after the Fourth Amendment Effective Date, Borrower shall prepay the outstanding principal amount of the Obligations in accordance with Section 2.4(f)(ii) in an amount equal to the lesser of (x) 100% of the Net Cash Proceeds (including condemnation awards and payments in lieu thereof) received by such Person in connection with such sales or dispositions, or (y) 100% of the Net Orderly Liquidation Value of such Accounts and/or Equipment at such time identified in the most recent appraisal ordered and obtained by Agent subject to such sale or disposition; and  
(2) Within 3 Business Days of the date of receipt (or if an Activation Instruction (as defined in the Guaranty and Security Agreement) is in effect concurrently with receipt) by Borrower or any of its Subsidiaries of the Net Cash Proceeds of any voluntary or involuntary sale or disposition by Borrower or any of its Subsidiaries of assets other than Accounts or Equipment (including casualty losses or condemnations but excluding sales or dispositions which qualify as Permitted Dispositions under clauses (b), (c), (d), (e), (j), (k), (l), (m), or (n) of the definition of Permitted Dispositions), Borrower shall prepay the outstanding principal amount of the Obligations in accordance with Section 2.4(f)(ii) in an amount equal to 100% of such Net Cash Proceeds (including condemnation awards and payments in lieu thereof) received by such Person in connection with such sales or dispositions; provided that, so long as (A) no Default or Event of Default shall have occurred and is continuing or would result therefrom, (B) Borrower shall have given Agent prior written notice of Borrower's intention to apply such monies to the costs of replacement of the properties or assets that are the subject of such sale or disposition or the cost of purchase or construction of other assets useful in the business of Borrower or its Subsidiaries, (C) the monies are held in a Deposit Account in which Agent has a perfected first-priority security interest, and (D) Borrower or its Subsidiaries, as applicable, complete such replacement, purchase, or construction within 180 days after the initial receipt of such monies, then the Loan Party whose assets were the subject of such disposition shall have the option to apply such monies to the costs of replacement of the assets that are the subject of such sale or disposition or the costs of purchase or construction of other assets useful in the business of such Loan Party unless and to the extent that such applicable period shall have expired without such replacement, purchase, or construction being made or completed, in which case, any amounts remaining in the Deposit Account referred to in clause (C) above shall be paid to Agent and applied in accordance with Section 2.4(f)(ii).  
Nothing contained in this Section 2.4(e)(ii) shall permit Borrower or any of its Subsidiaries to sell or otherwise dispose of any assets other than in accordance with Section 6.4.
(c)Section 2.10(c) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

(c)    Field Examination and Other Fees.  Borrower shall pay to Agent, field examination, appraisal, and valuation fees and charges, as and when incurred or chargeable, as follows (i) a fee of $1,000 per day, per examiner, plus reasonable out-of-pocket expenses (including travel, meals, and lodging) for each field examination of Borrower and its 

-3-

Subsidiaries performed by personnel employed by Agent, and (ii) the fees or charges paid or incurred by Agent (but, in any event, no less than a charge of $1,000 per day, per Person, plus reasonable out-of-pocket expenses (including travel, meals, and lodging)) if it elects to employ the services of one or more third Persons to perform field examinations of Borrower or its Subsidiaries, to establish electronic collateral reporting systems, or to appraise the Collateral, or any portion thereof; provided, that so long as no Event of Default shall have occurred and be continuing, Borrower shall not be obligated to reimburse Agent for more than 2 field examinations during any 12 consecutive months (unless Excess Availability exceeds $175,000,000 at all times during such 12 consecutive months, in which case Borrower shall not be obligated to reimburse Agent for more than 1 field examination in such 12 consecutive months), or more than 4 full appraisals (or desktop appraisals, at Agent's discretion) of the Equipment during any 12 consecutive months.
(d)Section 6.3(a) of the Credit Agreement is hereby amended and restated to read in its entirety as follows:

(a)    Other than in order to consummate a Permitted Acquisition, enter into any merger, consolidation, reorganization, or recapitalization, or reclassify its Equity Interests, except for (i) any merger between Loan Parties, provided, that Borrower must be the surviving entity of any such merger to which it is a party, (ii) any merger between a Loan Party and a Subsidiary of such Loan Party that is not a Loan Party so long as such Loan Party is the surviving entity of any such merger, and (iii) any merger between Subsidiaries of Borrower that are not Loan Parties (for the avoidance of doubt, in no event shall Nuverra Rocky Mountain be permitted to merge or consolidate into any Loan Party or Subsidiary of any Loan Party).  
(e)Section 6.10 of the Credit Agreement is hereby amended by (i) amending clause (c) thereof the delete the word "and" at the end thereof, (ii) amending and restating clause (d) thereof to read in its entirety as follows, and (iii) inserting a new clause (e) at the end thereof to read in its entirety as follows: 

(d)    transactions permitted by clause (p) of the definition of "Permitted Investment", and transactions permitted by Section 6.3 or Section 6.7, or any Permitted Intercompany Advance, and
(e)    Borrower may (i) enter into a service agreement, in form and substance reasonably satisfactory to Agent, with Nuverra Rocky Mountain for the provision of payroll, human resources, legal, accounting, tax reporting and filing and other administrative or similar services, and (ii) perform all transactions contemplated by such service agreement, including the payment or reimbursement of reasonable fees and expenses incurred pursuant thereto.
(f)Schedule 1.1 to the Credit Agreement is hereby amended by adding each of the following defined terms in their proper alphabetical order:

"Appraisal Reserves" means, as of any date of determination, a reserve in the amount of $19,750,000 to establish and maintain with respect to the Borrowing Base and the Maximum Revolver Amount; provided, that such reserve shall be reduced to $0 upon the occurrence of the implementation of the Fourth Amendment Appraisal.

-4-

"Eligible Equipment NBV Advance Rate" means 94%; provided, that such rate shall decrease by one percentage point on the first day of each calendar month beginning on February 1, 2016, until reduced to 70%.
"Eligible Equipment NOLV Advance Rate" means 84%; provided, that such rate shall decrease by one percentage point on the first day of each calendar month beginning on February 1, 2016, until reduced to 60%.
"Fourth Amendment Effective Date" means November 2, 2015.
"Nuverra Rocky Mountain" means Nuverra Rocky Mountain Pipeline, LLC, a Delaware limited liability company, together with any direct or indirect subsidiaries thereof formed or acquired after the Fourth Amendment Effective Date, and any successors or assigns of the foregoing entities (provided, that in no event shall any such successors or assigns be a Loan Party or other direct or indirect Subsidiary of a Loan Party).
"Fourth Amendment Appraisal" means the appraisal of the Net Orderly Liquidation Value of Eligible Equipment in form and substance satisfactory to Agent prepared by Great American Group Advisory and Valuation Services, LLC, and finalized on or after the Fourth Amendment Effective Date.
"Pipeline Reserves" means, as of any date of determination, a reserve of the lesser of (i) $5,000,000 and (ii) the aggregate amount of any Investments made by any Loan Party in Nuverra Rocky Mountain pursuant to clause (p) of the definition of Permitted Investments, to establish and maintain with respect to the Borrowing Base; provided, however, that no Investments made pursuant to clause (o) of the definition of Permitted Investments shall constitute Pipeline Reserves.
(g)Schedule 1.1 of the Credit Agreement is hereby amended to amend and restate the following definitions each in its entirety to read as follows:

"Applicable Margin" means, as of any date of determination and with respect to Base Rate Loans or LIBOR Rate Loans, as applicable, the applicable margin set forth in the following table that corresponds to the Average Excess Availability (without giving effect to any Interest Payment Reserves or Appraisal Reserves) of Borrower for the most recently completed month:
	
				
	Level
	Average Excess 
Availability
	Applicable Margin Relative to Base Rate Loans (the "Base Rate Margin")
	Applicable Margin Relative to LIBOR Rate Loans (the "LIBOR Rate Margin")

	I
	> $50,000,000
	1.00 percentage points
	2.00 percentage points

	II
	< $50,000,000 and > $25,000,000
	1.25 percentage points
	2.25 percentage points

	III
	< $25,000,000
	1.50 percentage points
	2.50 percentage points

-5-

The Applicable Margin shall be re-determined as of the first day of each calendar month of Borrower.
"Applicable Unused Line Fee Percentage" means, as of any date of determination, the applicable percentage set forth in the following table that corresponds to the Average Revolver Usage of Borrower for the most recently completed month as determined by Agent in its Permitted Discretion:
	
			
	Level
	Average Revolver Usage
	Applicable Unused Line Fee Percentage

	I
	> $62,500,000
	0.25 percentage points

	II
	< $62,500,000
	0.375 percentage points

The Applicable Unused Line Fee Percentage shall be re-determined on the first date of each month by Agent.
"Borrowing Base" means, as of any date of determination, the result of:
(a)the sum of (x) 85% of the amount of Eligible Accepted Accounts and (y) the lesser of $12,500,000 and 85% of the amount of Eligible Ticket Held Accounts, less the amount, if any, of the Dilution Reserve, plus

(b)(1) prior to January 1, 2016, the lower of

(i)the product of 95% multiplied by the net book value (calculated in accordance with GAAP on a basis consistent with Borrower's historical accounting practices) of Eligible Equipment at such time, and

(ii)the sum of (x) the product of 85% multiplied by the Net Orderly Liquidation Value of Eligible Equipment at such time identified in the most recent Equipment appraisal ordered and obtained by Agent plus (y) the product of 85% of the hard cost (as reflected in the invoice therefor and excluding tax, freight, installation charges and other soft costs) of Eligible Equipment acquired by a Loan Party as new and unused after the date of the most recent Equipment appraisal ordered and obtained by Agent and not identified in such appraisal,

(2) on or after January 1, 2016, the lower of
(i)        the product of the Eligible Equipment NBV Advance Rate multiplied by the net book value (calculated in accordance with GAAP on a basis consistent with Borrower's historical accounting practices) of Eligible Equipment at such time, and

(ii)        the sum of (x) the product of the Eligible Equipment NOLV Advance Rate multiplied by the Net Orderly Liquidation Value of Eligible Equipment at such time identified in the most recent Equipment appraisal ordered and obtained by Agent plus (y) the product of the Eligible Equipment NOLV 

-6-

Advance Rate multiplied by the hard cost (as reflected in the invoice therefor and excluding tax, freight, installation charges and other soft costs) of Eligible Equipment acquired by a Loan Party as new and unused after the date of the most recent Equipment appraisal ordered and obtained by Agent and not identified in such appraisal; minus
(c)the aggregate amount of Receivables Reserves, Bank Product Reserves, Equipment Reserves, Interest Payment Reserves, Appraisal Reserves, Pipeline Reserves and other Reserves, if any, established by Agent under Section 2.1(c) of the Agreement.

"Covenant Testing Period" means a period (a) commencing on the last day of the fiscal month of Borrower most recently ended on or prior to a Covenant Trigger Date and for which Agent has received financial statements required to be delivered pursuant to Schedule 5.1 and (b) ending on the first day after such Covenant Trigger Date that Excess Availability has equaled or exceeded the greater of (i) $15,625,000 and (ii) 12.5% of the Maximum Revolver Amount for 90 consecutive days.
"Covenant Trigger Date" means any day on which Borrower fails to maintain Excess Availability in an amount at least equal to the greater of (i) $15,625,000, and (ii) 12.5% of the Maximum Revolver Amount.
"Maximum Revolver Amount" means $125,000,000, as decreased by the amount of reductions in the Revolver Commitments made in accordance with Section 2.4(c) of the Agreement.
(h)Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "EBITDA" to (i) amend and restate clause (a) thereof in its entirety to read as follows: "(a) Borrower's consolidated net earnings (or loss) (it being understood that Borrower's consolidated net earnings (or loss) shall not include any earnings (or loss) attributable to Nuverra Rocky Mountain for any period that Nuverra Rocky Mountain is not a Guarantor), minus"; and (ii) insert a new clause (d) immediately following clause (c) thereof to read in its entirety as follows:

Plus (d) for any period that Nuverra Rocky Mountain is not a Guarantor, cash dividends received from Nuverra Rocky Mountain during such period.
(i)Effective as of July 1, 2015, Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "Permitted Indebtedness" to (i) remove the word "and" at the end of clause (r) thereof, (ii) rename clause (s) thereof as clause (t), and (iii) insert a new clause (s) in lieu thereof to read as follows:

(s)    unsecured Indebtedness of Borrower pursuant to that certain Promissory Note, dated as of June 9, 2015, by Borrower in favor of S&D Holdings, LLC, a Pennsylvania limited liability company, in an aggregate principal amount not to exceed $7,500,000; and
(j)Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "Permitted Investment" to (i) remove the word "and" at the end of clause (n) thereof, (ii) rename clause (o) thereof as clause (q), and (iii) insert new clauses (o) and (p) in lieu thereof to read as follows:

-7-

(o)    capitalized Investments made in connection with the construction, installation, maintenance and operation of an approximately 150-mile pipeline network in McKenzie County, North Dakota, including any extensions or alterations thereof, in an aggregate amount not to exceed $3,000,000;
(p)    Investments in Nuverra Rocky Mountain in an aggregate amount not to exceed $5,000,000 so long as (i) no Event of Default has occurred and is continuing or would result from the making of such Investment, and (ii) Borrower has given Agent at least three (3) Business Days' prior written notice of such Investment; and
(k)Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "Permitted Liens" to (i) remove the word "and" at the end of clause (r) thereof, (ii) rename clause (s) thereof as clause (t), and (iii) insert new clause (s) in lieu thereof to read as follows:

(s)    Liens on the Equity Interests of Nuverra Rocky Mountain, so long as such Liens are subordinated to Agent's Lien on terms and conditions acceptable to Agent; and
(l)Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "Reserves" by deleting the initial parenthetical therein and inserting "(other than Receivable Reserves, Bank Product Reserves, Equipment Reserves, Interest Payment Reserves, Appraisal Reserves and Pipeline Reserves)" in lieu thereof.

(m)Schedule 1.1 of the Credit Agreement is hereby amended to amend the defined term "Subsidiary" by inserting "; provided, that "Subsidiary" shall not include Nuverra Rocky Mountain." at the end of such defined term.

(n)Schedule C-1 to the Credit Agreement is replaced in its entirety with Schedule C-1 attached hereto.

4.Effectiveness of the Amendment; Continuing Effect.  Except as expressly set forth in Sections 2 and 3 of this Amendment, nothing in this Amendment shall constitute a modification or alteration of the terms, conditions or covenants of the Credit Agreement or any other Loan Document, or a waiver of any other terms or provisions thereof, and the Credit Agreement and the other Loan Documents shall remain unchanged and shall continue in full force and effect, in each case as amended hereby.  This Amendment is a Loan Document.

5.Reaffirmation and Confirmation.  Borrower hereby ratifies, affirms, acknowledges and agrees that the Credit Agreement and the other Loan Documents to which it is a party represent the valid, enforceable and collectible obligations of Borrower, and further acknowledges that there are no existing claims, defenses, personal or otherwise, or rights of setoff whatsoever with respect to the Credit Agreement or any other Loan Document.  Borrower hereby agrees that this Amendment in no way acts as a release or relinquishment of the Liens and rights securing payments of the Obligations.  The Liens and rights securing payment of the Obligations are hereby ratified and confirmed by Borrower in all respects. 

6.Conditions to Effectiveness.  This Amendment shall become effective upon the satisfaction of each of the following conditions precedent, in each case satisfactory to Agent in all respects:

(a)Agent shall have received a copy of this Amendment executed and delivered by Agent, the Lenders, and the Loan Parties;

-8-

(b)Agent shall have received a copy of an amendment to the Guaranty and Security Agreement executed and delivered by the Loan Parties and Agent, in form and substance satisfactory to Agent;

(c)Agent shall have received the Amendment Fee from Borrower; 

(d)Agent shall have received amended and restated promissory notes from Borrower; and

(e)no Default or Event of Default shall have occurred and be continuing on the date hereof or as of the date of the effectiveness of this Amendment.

7.Representations and Warranties.  In order to induce Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Agent and Lenders that:

(a)after giving effect to this Amendment, all representations and warranties contained in the Loan Documents to which Borrower is a party are true, correct and complete in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the date of this Amendment, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true, correct and complete in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of such earlier date);

(b)no Default or Event of Default has occurred and is continuing; and

(c)this Amendment and the Loan Documents, as amended hereby, constitute legal, valid and binding obligations of Borrower and are enforceable against Borrower in accordance with their respective terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors' rights generally.

8.Amendment Fee.  In connection with this Amendment, Borrower agrees to pay to Agent, for the account of the Lenders on a pro rata basis, an amendment fee (the "Amendment Fee") of $225,000, which fee is due and payable on the date hereof, and fully earned and non-refundable on the date hereof.  The Amendment Fee is in addition to and not net of any fees previously paid by Borrower or any Loan Party pursuant to any Loan Document.  Agent hereby is expressly authorized by Borrower to (x) charge such amounts due and owing to the Loan Account in accordance with the terms of the Credit Agreement, and (y) designate such amounts as a Revolving Loan under the Credit Agreement.

9.Post-Closing Covenant.  Within three (3) Business Days (or such later date as Agent may agree to in writing in its sole discretion) of the execution of the JV Agreement, Borrower shall deliver to Agent a fully executed, non-redacted copy of the JV Agreement.  Failure to comply with the provisions of this Section 9 shall constitute an immediate Event of Default.

-9-

10.Miscellaneous.

(a)Expenses.  Borrower agrees to pay on demand all reasonable costs and expenses of Agent (including reasonable attorneys' fees) incurred in connection with the preparation, negotiation, execution, delivery and administration of this Amendment and all other instruments or documents provided for herein or delivered or to be delivered hereunder or in connection herewith.  All obligations provided herein shall survive any termination of this Amendment and the Credit Agreement as amended hereby.
(b)Choice of Law and Venue; Jury Trial Waiver; Reference Provision.  Without limiting the applicability of any other provision of the Credit Agreement or any other Loan Document, the terms and provisions set forth in Section 12 of the Credit Agreement are expressly incorporated herein by reference.

(c)Counterparts.  This Amendment may be executed in any number of counterparts, and by the parties hereto on the same or separate counterparts, and each such counterpart, when executed and delivered, shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Amendment.  Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission shall be equally effective as delivery of an original executed counterpart of this Agreement.

(d)Severability.  Each provision of this Amendment shall be severable from every other provision of this Amendment for the purpose of determining the legal enforceability of any specific provision.

11.Release.

(a)In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of Borrower and each Guarantor that executes a Consent and Reaffirmation to this Amendment, on behalf of itself and its successors, assigns, and other legal representatives (Borrower, each Guarantor and all such other Persons being hereinafter referred to collectively as the "Releasors" and individually as a "Releasor"), hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent, Issuing Bank and Lenders, and their successors and assigns, and their present and former shareholders, Affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Issuing Bank, each Lender and all such other Persons being hereinafter referred to collectively as the "Releasees" and individually as a "Releasee"), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set‐off, demands and liabilities whatsoever (individually, a "Claim" and collectively, "Claims") of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which any Releasor may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, in any way related to or in connection with the Credit Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.

(b)Each of Borrower and each Guarantor that executes a Consent and Reaffirmation to this Amendment understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.

(c)Each of Borrower and each Guarantor that executes a Consent and Reaffirmation to this Amendment agrees that no fact, event, circumstance, evidence or transaction which could now be 

-10-

asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

[Signature Page Follows]

-11-

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized and delivered as of the date first above written.
	
		
	NUVERRA ENVIRONMENTAL SOLUTIONS, INC., as Borrower 

	By: 
	/s/ Joseph M. Crabb

	Name: Joseph M. Crabb

	Title: Executive Vice President & Chief Legal Officer

	
		
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent and as a Lender

	By: 
	/s/ Zachary Buchanan

	Name: Zachary Buchanan

	Title: AVP

	
		
	BANK OF AMERICA, N.A., as a Lender 

	By: 
	/s/ Lauren Trussell

	Name: Lauren Trussell

	Title: Vice President

	
		
	CITIZENS BANK OF PENNSYLVANIA, as a Lender 

	By: 
	/s/ Josh Bailey

	Name: Josh Bailey

	Title: Vice President

	
		
	CAPITAL ONE BUSINESS CREDIT CORP., as a Lender 

	By: 
	/s/ Edward Behnen

	Name: Edward Behnen

	Title: Vice President

	
		
	CIT FINANCE LLC, as a Lender 

	By: 
	/s/ Stewart McLeod

	Name: Stewart McLeod

	Title: Director

CONSENT AND REAFFIRMATION
Each of the undersigned (each a "Guarantor") hereby (i) acknowledges receipt of a copy of the foregoing Fourth Amendment, Consent and Release to Amended and Restated Credit Agreement (terms defined therein and used, but not otherwise defined, herein shall have the meanings assigned to them therein); (ii) consents to Borrower's execution and delivery thereof; (iii) agrees to be bound thereby, including Section 11 of the foregoing Fourth Amendment, Consent and Release to Amended and Restated Credit Agreement; and (iv) affirms that nothing contained therein shall modify in any respect whatsoever any Loan Documents to which the undersigned is a party and reaffirms that each such Loan Document is and shall continue to remain in full force and effect.  Although each Guarantor has been informed of the matters set forth herein and has acknowledged and agreed to same, each Guarantor understands that Agent and Lenders have no obligation to inform such Guarantor of such matters in the future or to seek such Guarantor's acknowledgment or agreement to future consents, amendments or waivers, and nothing herein shall create such a duty.

	
		
	HECKMANN WATER RESOURCES CORPORATION

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	HECKMANN WATER RESOURCES (CVR), INC. 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	1960 WELL SERVICES, LLC

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	HEK WATER SOLUTIONS, LLC

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	APPALACHIAN WATER SERVICES, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	BADLANDS POWER FUELS, LLC, a Delaware limited liability company 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	BADLANDS POWER FUELS, LLC, a North Dakota limited liability company 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	LANDTECH ENTERPRISES, L.L.C. 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	BADLANDS LEASING, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	IDEAL OILFIELD DISPOSAL, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	NUVERRA ROCKY MOUNTAIN PIPELINE, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	NUVERRA TOTAL SOLUTIONS, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	NES WATER SOLUTIONS, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

	
		
	HECKMANN WOODS CROSS, LLC 

	By: 
	/s/ Sean D. Hawkins

	Name: Sean D. Hawkins

	Title: Vice President and Assistant Secretary

Schedule C-1 
 
Commitments

	
		
	Lender
	Revolver Commitment

	Wells Fargo Bank, National Association
	$38,265,306

	Bank of America, N.A.
	$25,510,204

	Citizens Bank of Pennsylvania
	$25,510,204

	Capital One Business Credit Corp.
	$17,857,143

	CIT Finance LLC
	$17,857,143

	All Lenders
	$125,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]